Pulmatrix Book Value Per Share vs Price To Sales Ratio Analysis

PULM Stock

USD 6.29 0.25 4.14%

Pulmatrix financial indicator trend analysis is much more than just breaking down Pulmatrix prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Pulmatrix is a good investment. Please check the relationship between Pulmatrix Book Value Per Share and its Price To Sales Ratio accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pulmatrix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

To learn how to invest in Pulmatrix Stock, please use our How to Invest in Pulmatrix guide.

Book Value Per Share vs Price To Sales Ratio

Book Value Per Share vs Price To Sales Ratio Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Pulmatrix Book Value Per Share account and Price To Sales Ratio. At this time, the significance of the direction appears to have no relationship.

The correlation between Pulmatrix's Book Value Per Share and Price To Sales Ratio is 0.02. Overlapping area represents the amount of variation of Book Value Per Share that can explain the historical movement of Price To Sales Ratio in the same time period over historical financial statements of Pulmatrix, assuming nothing else is changed. The correlation between historical values of Pulmatrix's Book Value Per Share and Price To Sales Ratio is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Book Value Per Share of Pulmatrix are associated (or correlated) with its Price To Sales Ratio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Price To Sales Ratio has no effect on the direction of Book Value Per Share i.e., Pulmatrix's Book Value Per Share and Price To Sales Ratio go up and down completely randomly.

Correlation Coefficient

0.02

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Book Value Per Share

The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Pulmatrix stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Pulmatrix sales, a figure that is much harder to manipulate than other Pulmatrix multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Most indicators from Pulmatrix's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Pulmatrix current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pulmatrix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

To learn how to invest in Pulmatrix Stock, please use our How to Invest in Pulmatrix guide.At this time, Pulmatrix's Selling General Administrative is very stable compared to the past year. As of the 27th of November 2024, Enterprise Value Over EBITDA is likely to grow to 0.29, while Sales General And Administrative To Revenue is likely to drop 0.85.

Pulmatrix fundamental ratios Correlations

	Total Stockholder Equity	Retained Earnings	Common Stock Shares Outstanding	Other Stockholder Equity	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Non Current Liabilities Total	Inventory	Other Current Assets	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Common Stock
Total Stockholder Equity		-0.61	0.55	0.67	0.93	-0.47	0.51	0.22	0.21	0.45	-0.85	0.49	0.9	0.33	0.54	0.9	-0.01	-0.23	0.53	0.0	0.74	0.46	0.17	0.88	-0.47	0.62
Retained Earnings	-0.61		-0.78	-0.96	-0.76	0.88	-0.77	-0.6	-0.59	-0.89	0.77	-0.84	-0.62	-0.45	-0.63	-0.62	-0.3	-0.05	-0.45	-0.1	-0.75	-0.75	-0.55	-0.65	0.9	-0.92
Common Stock Shares Outstanding	0.55	-0.78		0.68	0.61	-0.45	0.39	0.24	0.79	0.48	-0.59	0.79	0.65	0.06	0.83	0.65	0.14	-0.49	0.58	-0.32	0.66	0.48	0.77	0.65	-0.5	0.91
Other Stockholder Equity	0.67	-0.96	0.68		0.81	-0.89	0.8	0.59	0.42	0.89	-0.83	0.73	0.66	0.47	0.52	0.66	0.28	0.1	0.37	0.2	0.79	0.76	0.37	0.69	-0.89	0.85
Total Assets	0.93	-0.76	0.61	0.81		-0.64	0.64	0.53	0.33	0.67	-0.91	0.59	0.91	0.41	0.57	0.91	0.29	-0.1	0.63	0.1	0.8	0.75	0.28	0.92	-0.65	0.72
Short Long Term Debt Total	-0.47	0.88	-0.45	-0.89	-0.64		-0.76	-0.65	-0.26	-0.98	0.65	-0.62	-0.41	-0.58	-0.3	-0.41	-0.31	-0.33	-0.09	-0.33	-0.65	-0.7	-0.22	-0.45	0.98	-0.67
Other Current Liab	0.51	-0.77	0.39	0.8	0.64	-0.76		0.56	0.31	0.78	-0.79	0.62	0.42	0.58	0.34	0.42	0.26	0.32	0.35	0.19	0.6	0.63	0.28	0.45	-0.78	0.6
Total Current Liabilities	0.22	-0.6	0.24	0.59	0.53	-0.65	0.56		0.13	0.74	-0.55	0.28	0.4	0.2	0.09	0.4	0.85	0.44	0.3	0.5	0.28	0.89	0.09	0.49	-0.61	0.42
Property Plant And Equipment Net	0.21	-0.59	0.79	0.42	0.33	-0.26	0.31	0.13		0.35	-0.23	0.83	0.24	0.27	0.86	0.24	0.07	-0.35	0.67	-0.54	0.45	0.38	0.99	0.24	-0.4	0.73
Current Deferred Revenue	0.45	-0.89	0.48	0.89	0.67	-0.98	0.78	0.74	0.35		-0.66	0.66	0.42	0.6	0.35	0.42	0.43	0.33	0.21	0.29	0.66	0.81	0.31	0.48	-0.98	0.69
Net Debt	-0.85	0.77	-0.59	-0.83	-0.91	0.65	-0.79	-0.55	-0.23	-0.66		-0.51	-0.88	-0.24	-0.48	-0.88	-0.28	0.04	-0.49	-0.25	-0.67	-0.68	-0.18	-0.89	0.62	-0.73
Accounts Payable	0.49	-0.84	0.79	0.73	0.59	-0.62	0.62	0.28	0.83	0.66	-0.51		0.39	0.57	0.74	0.39	0.1	-0.11	0.64	-0.23	0.67	0.53	0.81	0.4	-0.73	0.83
Cash	0.9	-0.62	0.65	0.66	0.91	-0.41	0.42	0.4	0.24	0.42	-0.88	0.39		0.0	0.56	1.0	0.21	-0.35	0.57	0.11	0.62	0.58	0.19	0.99	-0.38	0.69
Non Current Assets Total	0.33	-0.45	0.06	0.47	0.41	-0.58	0.58	0.2	0.27	0.6	-0.24	0.57	0.0		0.18	0.0	-0.02	0.39	0.25	-0.09	0.6	0.4	0.27	0.02	-0.67	0.23
Non Currrent Assets Other	0.54	-0.63	0.83	0.52	0.57	-0.3	0.34	0.09	0.86	0.35	-0.48	0.74	0.56	0.18		0.56	0.0	-0.4	0.66	-0.54	0.53	0.37	0.86	0.54	-0.39	0.77
Cash And Short Term Investments	0.9	-0.62	0.65	0.66	0.91	-0.41	0.42	0.4	0.24	0.42	-0.88	0.39	1.0	0.0	0.56		0.21	-0.35	0.57	0.11	0.62	0.58	0.19	0.99	-0.38	0.69
Net Receivables	-0.01	-0.3	0.14	0.28	0.29	-0.31	0.26	0.85	0.07	0.43	-0.28	0.1	0.21	-0.02	0.0	0.21		0.39	0.29	0.34	0.0	0.72	0.07	0.32	-0.29	0.14
Common Stock Total Equity	-0.23	-0.05	-0.49	0.1	-0.1	-0.33	0.32	0.44	-0.35	0.33	0.04	-0.11	-0.35	0.39	-0.4	-0.35	0.39		-0.28	0.45	-0.19	0.17	-0.32	-0.28	-0.29	-0.27
Non Current Liabilities Total	0.53	-0.45	0.58	0.37	0.63	-0.09	0.35	0.3	0.67	0.21	-0.49	0.64	0.57	0.25	0.66	0.57	0.29	-0.28		-0.28	0.44	0.55	0.65	0.58	-0.2	0.55
Inventory	0.0	-0.1	-0.32	0.2	0.1	-0.33	0.19	0.5	-0.54	0.29	-0.25	-0.23	0.11	-0.09	-0.54	0.11	0.34	0.45	-0.28		-0.2	0.26	-0.6	0.15	-0.2	-0.05
Other Current Assets	0.74	-0.75	0.66	0.79	0.8	-0.65	0.6	0.28	0.45	0.66	-0.67	0.67	0.62	0.6	0.53	0.62	0.0	-0.19	0.44	-0.2		0.59	0.42	0.62	-0.7	0.72
Total Liab	0.46	-0.75	0.48	0.76	0.75	-0.7	0.63	0.89	0.38	0.81	-0.68	0.53	0.58	0.4	0.37	0.58	0.72	0.17	0.55	0.26	0.59		0.34	0.65	-0.72	0.61
Property Plant And Equipment Gross	0.17	-0.55	0.77	0.37	0.28	-0.22	0.28	0.09	0.99	0.31	-0.18	0.81	0.19	0.27	0.86	0.19	0.07	-0.32	0.65	-0.6	0.42	0.34		0.19	-0.36	0.67
Total Current Assets	0.88	-0.65	0.65	0.69	0.92	-0.45	0.45	0.49	0.24	0.48	-0.89	0.4	0.99	0.02	0.54	0.99	0.32	-0.28	0.58	0.15	0.62	0.65	0.19		-0.42	0.69
Short Term Debt	-0.47	0.9	-0.5	-0.89	-0.65	0.98	-0.78	-0.61	-0.4	-0.98	0.62	-0.73	-0.38	-0.67	-0.39	-0.38	-0.29	-0.29	-0.2	-0.2	-0.7	-0.72	-0.36	-0.42		-0.7
Common Stock	0.62	-0.92	0.91	0.85	0.72	-0.67	0.6	0.42	0.73	0.69	-0.73	0.83	0.69	0.23	0.77	0.69	0.14	-0.27	0.55	-0.05	0.72	0.61	0.67	0.69	-0.7

Click cells to compare fundamentals

Pulmatrix Account Relationship Matchups

Pulmatrix fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Stockholder Equity	11.0M	23.1M	47.4M	31.1M	18.0M	18.9M
Retained Earnings	(215.2M)	(234.5M)	(254.6M)	(273.5M)	(287.6M)	(273.2M)
Common Stock Shares Outstanding	836.7K	1.4M	2.7M	3.4M	3.7M	3.8M
Other Stockholder Equity	226.2M	257.6M	301.0M	304.6M	305.6M	175.4M
Total Assets	36.1M	38.2M	58.8M	41.0M	34.0M	30.4M
Other Current Liab	2.5M	893K	(198K)	781K	518K	543.9K
Total Current Liabilities	17.2M	8.3M	4.4M	5.0M	3.9M	5.3M
Property Plant And Equipment Net	900K	1.9M	2.4M	945K	11.5M	12.0M
Current Deferred Revenue	13.4M	4.2M	939K	1.3M	618K	648.9K
Net Debt	(22.8M)	(29.9M)	(51.6M)	(34.8M)	(10.4M)	(10.9M)
Accounts Payable	600K	851K	839K	1.2M	1.9M	2.0M
Cash	23.4M	31.7M	53.8M	35.6M	19.2M	20.5M
Non Current Assets Total	4.7M	5.6M	4.0M	2.8M	13.1M	8.2M
Cash And Short Term Investments	23.4M	31.7M	53.8M	35.6M	19.2M	20.5M
Net Receivables	7.2M	84K	67K	1.3M	928K	1.0M
Liabilities And Stockholders Equity	36.1M	38.2M	58.8M	41.0M	34.0M	30.4M
Non Current Liabilities Total	7.9M	6.8M	6.9M	4.8M	12.1M	12.7M
Other Current Assets	221K	723K	871K	1.1M	1.1M	566.2K
Total Liab	25.1M	15.0M	11.4M	9.8M	16.0M	9.9M
Property Plant And Equipment Gross	900K	361.0	2.4M	945K	13.2M	13.9M
Total Current Assets	31.4M	32.5M	54.8M	38.1M	20.8M	22.2M
Short Term Debt	675K	2.3M	2.9M	1.7M	858K	815.1K
Net Tangible Assets	7.4M	19.6M	46.4M	31.1M	35.8M	37.6M
Retained Earnings Total Equity	(174.0M)	(194.6M)	(215.2M)	(234.5M)	(211.0M)	(221.6M)
Capital Surpluse	184.1M	206.4M	226.2M	257.6M	296.2M	191.7M
Property Plant Equipment	270K	1.9M	2.4M	945K	1.1M	991.8K
Net Invested Capital	11.0M	23.1M	46.4M	31.1M	18.0M	24.3M
Net Working Capital	14.2M	24.3M	50.3M	33.1M	16.9M	21.6M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Pulmatrix is a strong investment it is important to analyze Pulmatrix's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pulmatrix's future performance. For an informed investment choice regarding Pulmatrix Stock, refer to the following important reports:

How To Invest In Pulmatrix

Details

Is Pulmatrix Stock a good investment?

Details

What is Pulmatrix's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pulmatrix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

To learn how to invest in Pulmatrix Stock, please use our How to Invest in Pulmatrix guide.

You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pulmatrix. If investors know Pulmatrix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pulmatrix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.64)

Revenue Per Share

3.119

Quarterly Revenue Growth

(0.16)

Return On Assets

(0.30)

Return On Equity

(0.59)

The market value of Pulmatrix is measured differently than its book value, which is the value of Pulmatrix that is recorded on the company's balance sheet. Investors also form their own opinion of Pulmatrix's value that differs from its market value or its book value, called intrinsic value, which is Pulmatrix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pulmatrix's market value can be influenced by many factors that don't directly affect Pulmatrix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Pulmatrix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pulmatrix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pulmatrix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Pulmatrix Book Value Per Share vs Price To Sales Ratio Analysis

Book Value Per Share vs Price To Sales Ratio

Book Value Per Share vs Price To Sales Ratio Correlation Analysis

Correlation Coefficient

Book Value Per Share

Price To Sales Ratio

Pulmatrix fundamental ratios Correlations

Pulmatrix Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Pulmatrix fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Property Plant And Equipment Gross	+ 0.99	Property Plant And Equipment Net
Total Current Assets	+ 0.99	Cash
Total Current Assets	+ 0.99	Cash And Short Term Investments
Short Term Debt	+ 0.98	Short Long Term Debt Total
Total Assets	+ 0.93	Total Stockholder Equity

Short Term Debt	- 0.98	Current Deferred Revenue
Current Deferred Revenue	- 0.98	Short Long Term Debt Total
Other Stockholder Equity	- 0.96	Retained Earnings
Common Stock	- 0.92	Retained Earnings
Net Debt	- 0.91	Total Assets
Total Current Assets	- 0.89	Net Debt